Leadership dossier

W. Bryan Hubbard: Americans for Ibogaine CEO

A veteran attorney turned ibogaine policy advocate, W. Bryan Hubbard leads Americans for Ibogaine (AFI) as Chief Executive Officer, shaping a national effort to expand science‑based education, clinical research, and medically supervised access for people facing severe addiction, PTSD, and related conditions. For background, see the succinct overview at W. Bryan Hubbard’s official site.

Who he is, and the scope of the work

The operator

W. Bryan Hubbard serves as CEO of Americans for Ibogaine. Before his current role, he was the first chairman of the Kentucky Opioid Abatement Advisory Commission, where he worked within state government to oversee settlement funds aimed at addressing the opioid crisis. That governance background informs his approach to building coalitions outside the usual psychedelics subculture, including outreach across conservative policy channels.

Attorney Coalition Builder Public Policy

The issue at hand

Ibogaine, a psychoactive alkaloid from the African Tabernanthe iboga plant, has strong observational evidence for interrupting opioid and other substance‑use disorders, with emerging data in PTSD and traumatic brain injury. Yet in the United States it remains Schedule I—officially “no accepted medical use”—despite growing international clinical experience.

That gap is why people often look abroad while the U.S. works through trials and policy. Context from the north is visible through ibogaine treatment centers in Canada, which many Americans research as they evaluate present‑day options versus forthcoming domestic pathways.

Americans for Ibogaine under Hubbard’s leadership

Education and research

AFI’s mission is to advance science‑based education, clinical research, and responsible medical access to ibogaine therapy. The organization positions itself as a national voice for ibogaine, focusing on credible science, clinician engagement, and public‑health framing that prioritizes people with severe addiction and mental illness.

As stakeholders analyze chemistries, safety, and protocols, resources like an ibogaine HCl guide are frequently referenced for compound‑specific context, even while AFI continues to emphasize physician oversight and data‑driven standards.

Coalitions and policy channels

AFI concentrates on pragmatic needle‑moving: state experimentation, federal coordination, and structured access for those most likely to benefit. Hubbard and AFI have engaged national networks and state leaders to translate narrow federal pathways into usable systems, a strategy aligned with his earlier experience in opioid abatement policy.

Veterans—especially those with treatment‑resistant PTSD or opioid use disorder—remain at the heart of this advocacy, where existing treatments too often fall short.

Taped‑down cards from a policy inflection point

Advance science‑based education, clinical research, and responsible medical access to ibogaine therapy—prioritizing those with the most serious needs. AFI mission focus

The federal landscape shifted: an April 2026 executive order directed FDA and DEA to prioritize psychedelic drugs, including ibogaine compounds, for review, Right‑to‑Try pathways, and post‑Phase‑3 rescheduling. Policy context

States like Texas have already allocated $50 million toward FDA drug‑development trials in psychedelic therapies for veterans—a model other states can evaluate. State‑level momentum

What’s changing now vs. what remains constrained

Changing

Federal attention: explicit direction to prioritize ibogaine compounds alongside other psychedelics.
ARPA‑H support: at least $50 million earmarked to help states advance psychedelic treatments for serious mental illness.
Right‑to‑Try expanded in 2025 to include ibogaine for limited cases, primarily veterans with treatment‑resistant PTSD or opioid use disorder.
FDA‑overseen ibogaine trials are recruiting in the U.S., creating a legal pathway through clinical research.

Constrained

Schedule I status continues to restrict domestic access outside trials and narrow Right‑to‑Try scenarios.
Systems‑building is required at the state level to translate pathways into real‑world clinical options.
Many individuals still evaluate international care while U.S. frameworks mature; cost considerations remain central, as seen in discussions of the cost of ibogaine treatment in Mexico.

Practical contours of access

As of 2026, the only fully legal domestic path for most patients is participation in FDA‑supervised trials; limited Right‑to‑Try pathways exist, with a primary emphasis on veterans facing treatment‑resistant PTSD or opioid use disorder. AFI’s role in this moment is to help turn those pathways into usable systems—linking research sponsors, clinicians, and state partners so that policy becomes practice.

While frameworks evolve, individuals often compare international clinical settings with emerging U.S. options. The strategic challenge is not merely scientific validation, but coordinated implementation that upholds safety, medical oversight, and data transparency.

Questions people ask

Who is W. Bryan Hubbard?

He is the Chief Executive Officer of Americans for Ibogaine and a veteran attorney who previously chaired the Kentucky Opioid Abatement Advisory Commission. For a compact dossier, the ibogaine.wiki profile of Bryan Hubbard provides additional biographical texture.

What does Americans for Ibogaine do?

AFI advances science‑based education, supports clinical research, and advocates for medically supervised access to ibogaine therapy—particularly for veterans and people with severe addiction or mental illness—by coordinating with clinicians, researchers, and policymakers.

Is ibogaine legal in the United States?

Ibogaine remains a Schedule I controlled substance. Practical domestic access is limited to FDA‑overseen clinical trials and specific Right‑to‑Try cases. AFI focuses on expanding these lawful pathways while maintaining medical oversight and safety standards.

Why the veteran focus?

Veterans with treatment‑resistant PTSD and opioid use disorder are central to the policy conversation, reflected in state initiatives and federal direction to prioritize psychedelic medicines for serious mental illness. Hubbard and AFI’s work highlights these populations where conventional approaches may not suffice.

How are people navigating options today?

Many continue to monitor U.S. trials and narrow Right‑to‑Try avenues while evaluating international clinics. Comparative research sometimes includes resources like the Canadian clinic landscape, even as AFI and partners work to mature domestic systems.

Where the advocacy meets implementation

Americans for Ibogaine’s approach—science‑first, medically supervised, implementation‑minded—aligns with a new federal posture and accelerating state activity. Hubbard’s legal background and opioid governance experience position AFI to help translate policy into clinical reality for those most in need.

As frameworks solidify, the goal is simple and demanding: safe, data‑anchored access under physician care for conditions where status‑quo treatments fail.

Visit official profile